|
|
|
|
|||||
|
|
|
SALT LAKE CITY, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced Myriad management will participate in two upcoming healthcare conferences.
The presentations will be available through live audio webcast links in the investor information section of Myriad’s website at investor.myriad.com.
About Myriad Genetics
Myriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.
Investor Contact
Matt Scalo
(801) 584-3532
[email protected]
Media Contact
Kate Schraml
(224) 875-4493
[email protected]
| 8 hours | |
| Nov-10 | |
| Nov-10 | |
| Nov-06 | |
| Nov-04 | |
| Nov-04 | |
| Nov-04 | |
| Nov-03 | |
| Nov-03 | |
| Nov-03 | |
| Nov-03 | |
| Nov-03 | |
| Nov-01 | |
| Oct-31 | |
| Oct-31 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite